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Introduction
Growth is a sensitive marker of well-being in children. In
patients with juvenile idiopathic arthritis (JIA) both,
ongoing inflammation and corticosteroid treatment, may
affect linear growth adversely, potentially leading to irre-
versible growth retardation. Biologic treatment of JIA may
have the potential to enable normal growth in children
with JIA.
Objectives
To retrospectively evaluate the safety, clinical efficacy,
corticosteroid-dose and impact on linear growth of biolo-
gics in children with JIA in The center of the biological




- DMARDs-resistant polyarticular course of JIA
receiving anti-TNF treatment at least one year.
- Evaluation of response every 3 months by Pediatric
American College of Rheumatology Response Cri-
teria (ACR Paed).
Exclusion criteria:
- no growth expected boys: Tanner staging sexual
maturity score V plus age 17 before starting anti-TNF
treatment
- no growth expected girls: menarche at least two
years before starting anti-TNF treatment or menarche
at least a year before starting treatment plus Tanner
staging sexual maturity score IV
Growth velocity was defined by change of height in stan-
dard deviation (SD) score. To calculate exact SD score
software Rust CZ 2.0, based on anthropometric data of
Czech paediatric population - the nearest one to Slovak
paediatric population, was used. Catch-up was defined as
positive growth velocity.
Results
The group of 20 patients with expected growth (boys vs.
girls: 10 vs. 10; etanercept vs. adalimumab: 16 vs. 4) was
assessed. The mean age at anti-TNF treatment initiation
was 12.03 years (SD ± 4.44). Median duration of disease
was 3.25 years (range 0.89-10.23), 15 patients received cor-
ticosteroids in mean dose 0.273 mg/kg/day.
All patients were identified as “responders” (ACR Paed
30) at 3 months. One patient was a ...secondary non-
responder” at 6 months, but completed 12 months of
treatment. The daily dose of corticosteroids at 12 months
was significantly reduced to 0.07 mg/kg/day (p < 0.001)
and could be stopped in 10 of 15 patients. Growth catch-
up was observed in 16 of 20 patients with median growth
velocity being 0.325 (range -0.2 to 0.94). Two patients did
not show growth during the first year of treatment.
Conclusion
Anti-TNF treatment of JIA is highly effective and has a
rapid corticosteroid-sparing effect in DMARDs-resistant
JIA with polyarticular course. The clinical response is
accompanied by an increase in growth rate (catch-up) in
most cases.
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